Signase is a cancer therapeutics company developing small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. Signase was spun out of the M. D. Anderson Cancer Center.
Company (Alive / Active)
Texas, United States
|Investor||Investor Type||Location||Participating Rounds|
|Sunnyvale, California, United States||Acquired||Cardiac Pathways manufactures minimally invasive systems used by electrophysiologists to diagnose and treat cardiac tachyarrhythmias, which if untreated can cause palpitations, fainting, and sudden cardiac arrest. Cardiac Pathways' products consist principally of systems for performing ablation treatment and for diagnostic mapping.||Login to see details|
|Gaithersburg, Maryland, United States||IPO / Went public||GlycoMimetics is developing small molecule drugs that mimic the actions of carbohydrates using glycobiology. The company is focusing its initial efforts on therapeutics to treat inflammatory diseases such as cystic fibrosis and cancer.||Login to see details|
|Title||Application Date||Patent Date||Status
(Patent / Application)